Global Antifungal Drug Market Research Report (2021 to 2026) – by Infection Type, Type, Form, Therapeutic Indications and Region – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Antifungal Drug Market Research Report by Infection Type, Type, Form, Therapeutic Indications, and Region – Global Forecast to 2026 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering.

The Global Antifungal Drug Market size was estimated at USD 12.55 billion in 2020, is expected to reach USD 13.26 billion in 2021, and projected to grow at a CAGR of 6.00% reaching USD 17.81 billion by 2026.

Competitive Strategic Window

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Antifungal Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Antifungal Drug Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antifungal Drug Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antifungal Drug Market?

4. What is the competitive strategic window for opportunities in the Global Antifungal Drug Market?

5. What are the technology trends and regulatory frameworks in the Global Antifungal Drug Market?

6. What is the market share of the leading vendors in the Global Antifungal Drug Market?

7. What modes and strategic moves are considered suitable for entering the Global Antifungal Drug Market?

Market Dynamics

Drivers

• Growing prevalence of fungal infection due to climate
• High awareness levels pertaining to myriad fungal infections
• Increased demand for the drugs to combat the related diseases
• Favorable government initiative and corporate funds

Restraints

• Continued preference for conventional antifungal drugs
• Growing population with antifungal drug resistance

Opportunities

• Increased R&D funding and focus on product innovation
• Patent expiration of branded drugs

Challenges

• Potential side effects
• Presence of counterfeit drugs and resistance toward antifungal drugs

Companies Mentioned

• Abbott Laboratories
• Astellas Pharma Inc.
• Bayer HealthCare Pharmaceuticals LLC
• Cadila Pharmaceuticals Limited
• Cipla, Inc.
• Eli Lilly and Company
• Enzon Pharmaceuticals, Inc.
• G&W Laboratories LLC
• Gilead Sciences, Inc.
• Johnson & Johnson
• Kramer Laboratories, Inc.
• Lakewood-Amedex, Inc.
• Merck KGaA
• Novartis AG
• Pfizer, Inc.
• Ranbaxy Laboratories Limited
• Sanofi S.A.
• SCYNEXIS, Inc.
• Sigma-Aldrich, Inc.
• Wockhardt Limited

For more information about this report visit https://www.researchandmarkets.com/r/ocqzzu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900